Embryonated Chicken Tumor Xenografts Derived from Circulating Tumor Cells as a Relevant Model to Study Metastatic Dissemination: A Proof of Concept.
Alu sequences
CAM assay
CTCs
metastasis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Aug 2022
23 Aug 2022
Historique:
received:
10
06
2022
revised:
21
07
2022
accepted:
19
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Patient-Derived Xenografts (PDXs) in the Chorioallantoic Membrane (CAM) are a representative model for studying human tumors. Circulating Tumor Cells (CTCs) are involved in cancer dissemination and treatment resistance mechanisms. To facilitate research and deep analysis of these few cells, significant efforts were made to expand them. We evaluated here whether the isolation of fresh CTCs from patients with metastatic cancers could provide a reliable tumor model after a CAM xenograft. We enrolled 35 patients, with breast, prostate, or lung metastatic cancers. We performed microfluidic-based CTC enrichment. After 48-72 h of culture, the CTCs were engrafted onto the CAM of embryonated chicken eggs at day 9 of embryonic development (EDD9). The tumors were resected 9 days after engraftment and histopathological, immunochemical, and genomic analyses were performed. We obtained in ovo tumors for 61% of the patients. Dedifferentiated small tumors with spindle-shaped cells were observed. The epithelial-to-mesenchymal transition of CTCs could explain this phenotype. Beyond the feasibility of NGS in this model, we have highlighted a genomic concordance between the in ovo tumor and the original patient's tumor for constitutional polymorphism and somatic alteration in one patient. Alu DNA sequences were detected in the chicken embryo's distant organs, supporting the idea of dedifferentiated cells with aggressive behavior. To our knowledge, we performed the first chicken CAM CTC-derived xenografts with NGS analysis and evidence of CTC dissemination in the chicken embryo.
Identifiants
pubmed: 36077622
pii: cancers14174085
doi: 10.3390/cancers14174085
pmc: PMC9454737
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Region Auvergne Rhône-Alpes and Grenoble Alpes Metropole with the support from the CLARA (Cancéropôle Lyon Auvergne Rhone-Alpes)
ID : CVPPRCAN000163
Organisme : Region Auvergne Rhône-Alpes
ID : FUI24INOVOLINE
Références
Cells Tissues Organs. 2013;198(1):12-21
pubmed: 23774755
Cells. 2019 Sep 25;8(10):
pubmed: 31557946
J Vis Exp. 2011 May 30;(51):
pubmed: 21673636
Sci Rep. 2015 Aug 14;5:12635
pubmed: 26271202
Jpn J Cancer Res. 1991 Oct;82(10):1165-70
pubmed: 1955382
PLoS One. 2014 Aug 29;9(8):e106219
pubmed: 25170920
Sci Rep. 2020 Oct 29;10(1):18585
pubmed: 33122780
Am J Cancer Res. 2018 Aug 01;8(8):1642-1660
pubmed: 30210932
Science. 2014 Jul 11;345(6193):216-20
pubmed: 25013076
Br J Cancer. 2012 Jan 31;106(3):508-16
pubmed: 22187035
Cancers (Basel). 2022 Mar 14;14(6):
pubmed: 35326627
Clin Chem. 2012 May;58(5):936-40
pubmed: 22205690
Cancers (Basel). 2021 May 28;13(11):
pubmed: 34071445
Cancer Res. 2002 Dec 1;62(23):7083-92
pubmed: 12460930
JCO Clin Cancer Inform. 2021 Oct;5:1085-1095
pubmed: 34731027
Mol Med Rep. 2017 Dec;16(6):8781-8792
pubmed: 28990079
J Thorac Oncol. 2019 May;14(5):876-889
pubmed: 30735816
Technol Cancer Res Treat. 2013 Aug;12(4):295-309
pubmed: 23448577
Int J Cancer. 2011 Oct 1;129(7):1651-60
pubmed: 21128227
Sci Rep. 2020 Jan 17;10(1):539
pubmed: 31953491
Sci Rep. 2015 Dec 03;5:17533
pubmed: 26631983
Nat Rev Drug Discov. 2013 Mar;12(3):217-28
pubmed: 23449307
Cancer Drug Resist. 2022 Mar 16;5(1):245-260
pubmed: 35582538
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2020 Oct 9;10(1):16876
pubmed: 33037240
Oncogene. 2017 Mar 2;36(9):1211-1222
pubmed: 27669438
Cancers (Basel). 2020 Apr 07;12(4):
pubmed: 32272669
NPJ Precis Oncol. 2019 Oct 2;3:23
pubmed: 31602399
Cytometry A. 2018 Dec;93(12):1251-1254
pubmed: 30080307
Sci Rep. 2018 Jun 4;8(1):8524
pubmed: 29867159
Sci Transl Med. 2013 Apr 10;5(180):180ra48
pubmed: 23576814
J Vis Exp. 2019 Aug 14;(150):
pubmed: 31475991
Nat Med. 2014 Aug;20(8):897-903
pubmed: 24880617
Sci Rep. 2017 Oct 16;7(1):13202
pubmed: 29038571
Cancers (Basel). 2021 Mar 04;13(5):
pubmed: 33806378
J Hematol Oncol. 2019 May 14;12(1):48
pubmed: 31088479
Oncotarget. 2019 Dec 03;10(64):6885-6897
pubmed: 31839882
Cells. 2019 May 10;8(5):
pubmed: 31083409
Cancers (Basel). 2019 Oct 19;11(10):
pubmed: 31635038
Breast Cancer Res Treat. 2017 Jun;163(2):219-230
pubmed: 28271309
Cancer Res. 2009 Apr 1;69(7):2783-91
pubmed: 19293183
J Vis Exp. 2015 Oct 20;(105):53182
pubmed: 26555435
Int J Cancer. 2018 Apr 1;142(7):1440-1452
pubmed: 29143337
Cells Tissues Organs. 2022;211(2):222-237
pubmed: 33780951
Signal Transduct Target Ther. 2021 Nov 22;6(1):404
pubmed: 34803167